Besides, the current guidelines recommended that medication including angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), β-receptor blockers and mineralocorticoid receptor antagonist (MRA) can be used to improve myocardial remodeling after MI. The gene discussed is ACE; the disease is myocardial infarction.